Day One Biopharmaceuticals PEG Ratio

Day One Biopharmaceuticals (DAWN) currently reports a PEG ratio of 30.61. That is above the Healthcare sector average of 11.64. Use the charts on this page to explore Day One Biopharmaceuticals's PEG ratio history and peer comparisons.

Day One Biopharmaceuticals's PEG ratio of 30.61 is higher than the Healthcare sector average of 11.64. That is roughly 163.0% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The PEG ratio is a valuation multiple that relates Day One Biopharmaceuticals's market price to a fundamental measure such as earnings, sales, or book value. At 30.61, DAWN can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current PEG ratio of 30.61, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.64. From there, open related valuation or income-statement pages for Day One Biopharmaceuticals, and consider following DAWN for alerts when major investors trade the stock.

Day One Biopharmaceuticals is classified in the Healthcare sector. On PEG ratio, it currently shows 30.61 versus a sector average near 11.64. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DAWN with unrelated industries.